According to TipRanks.com, Belanger is a 2-star analyst with an average return of 0.1% and a 41.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evolus with a $15.20 average price target, representing a 20.8% upside. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $15.00 price target.
Evolus’ market cap is currently $734.8M and has a P/E ratio of -10.09.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EOLS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.
Read More on EOLS:
- Last Minute Thought: Buy or Sell AMD Stock Before Earnings?
- Greene Concepts Completes First Production Run of Happy Mellow Immune Support Beverage
- Nokia Corporation: Repurchase of own shares on 02.08.2022
- Arctic Glacier Issues Default Status Report Pursuant to National Policy 12-203
- TASEKO TO RELEASE SECOND QUARTER 2022 RESULTS